Previous 10 | Next 10 |
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference PR Newswire SALT LAKE CITY , Jan. 5, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announ...
Lipocine (NASDAQ:LPCN) announces that the first patient has been dosed in its Phase 2 proof-of-concept clinical study for the management of liver cirrhosis. Shares down 2.8% premarket at $1.06. The primary endpoint is change from baseline in Skeletal Muscle Index via computed tomogr...
LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS PR Newswire SALT LAKE CITY , Dec. 22, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic an...
Lipocine has obtained positive results in a phase 2 study using its drug LPCN1144 for the treatment of patients with NASH. TLANDO is being resubmitted to the FDA as a Class 1 resubmission with 2 months review time; possible FDA approval expected on January 28, 2022. It is estimate...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021 PR Newswire SALT LAKE CITY , Nov. 10, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorde...
5 Reddit Penny Stocks to Watch in November 2021 Finding penny stocks on Reddit is one of the most popular choices for investors to make. While not all penny stocks found on Reddit will be valuable, the discussion platform can be a great resource when creating a watchlist. One th...
The U.S. FDA has granted Fast Track Designation to Lipocine's (NASDAQ:LPCN) LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis (NASH). Shares up more than 9% premarket. LPCN 1144 was recently studied in the Liver Fat intervention with oral Testosterone ((L...
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH PR Newswire SALT LAKE CITY , Nov. 4, 2021 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrin...
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 Late Breaking Posters Will Feature Data From Phase 2 LiFT Study Investigating LPCN 1144 in NASH PR Newswire SALT LAKE C...
Energous (NASDAQ:WATT) +35% granted FCC approval for unlimited Distance over-the-air wireless charging Edesa Biotech (NASDAQ:EDSA) +29% reports favorable mortality reductions in COVID-19 study InflaRx (NASDAQ:IFRX) +21% after EUR 43.7M vilobelimab development grant En...
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...